证券代码：688389 证券简称：普门科技 公告编号：2025-064 深圳普门科技股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议召开时间：2025年9月2日（星期二）上午10:00-11:00 ● 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于2025年8月26日（星期二）至9月1日（星期一）16:00前登录 上证路演中心网站首页点击"提问预征集"栏目或通过深圳普门科技股份有限公 司（以下简称"公司"）邮箱bod@lifotronic.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 （三）会议召开方式：上证路演中心网络互动 三、参加人员 公司董事长刘先成先生，董事、总经理胡明龙先生，董事、副总经理曾映先 生，董事、财务总监王红女士，独立董事蔡翘梧先生、杨光辉 ...

深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 证券代码：688389 证券简称：普门科技 公告编号：2025-063 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后 的实际销售情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未 1 / 2 来业绩的具体影响。 敬请投资者理性投资，注意投资风险。 特此公告。 深圳普门科技股份有限公司董事会 一、医疗器械注册证的具体情况 | 产品名称 | 注册 | 注册证 | 注册证 | | 预期用途 | | --- | --- | --- | --- | --- | --- | | | 分类 | 编号 | 有效期至 | | | | β-人绒毛膜促性腺激素 （β-HCG | | 粤械注准 | | 年 | 用于体外定量测定人血清或血 浆中β-人绒毛 ...

Policy Developments - The National Health Commission and five other departments released measures to enhance the experience of family doctor contract services, focusing on improving service quality and health management for residents [2] Drug and Device Approvals - Novo Nordisk's Wegovy (semaglutide 2.4mg) received FDA approval for treating metabolic-associated fatty liver disease (MASH) with moderate to severe liver fibrosis, which is expected to boost sales [3] - Yiling Pharmaceutical's new traditional Chinese medicine, "Children's Lianhua Qinggan Granules," has received acceptance for its new drug registration application [4] - Pumen Technology obtained a medical device registration certificate for its high-sensitivity cardiac troponin I testing kit, which aids in diagnosing myocardial infarction [5] Financial Reports - Ping An Good Doctor reported a 19.5% increase in revenue to approximately 2.502 billion yuan and a net profit increase of 136.8% to 134 million yuan for the first half of the year [6] - Weier Pharmaceutical's revenue decreased by 2.1% to 674 million yuan, with a net profit decline of 7.77% to 72.77 million yuan in the same period [7] Capital Market Activities - Jianzhijia plans to sell its Qinhuangdao logistics center assets for approximately 24 million yuan, which does not constitute a related party transaction [8] - Gilead Sciences announced a placement of 52.4 million shares at a discount of about 9.9%, with expected net proceeds of approximately 467.69 million HKD, primarily for clinical trials related to obesity [9] Industry News - The National Disease Control Bureau reported a decline in new cases of Chikungunya fever in Foshan, with daily cases dropping from over 600 to below 100, indicating effective control measures [10] - A breakthrough study from Harvard University demonstrated the ability to induce human pluripotent stem cells to initiate meiosis, offering new hope for addressing infertility [11] Public Sentiment Alerts - Baiotai announced that Xinyu Qiheng reduced its stake by 0.78%, selling 3.2169 million shares and raising approximately 105 million yuan [12]

Group 1 - The core point of the article highlights that Pumen Technology's stock price decreased by 0.75% on August 19, closing at 14.49 yuan, with a total market capitalization of 6.209 billion yuan [1] - The company's main business is medical device manufacturing, with its medical device segment accounting for 98.56% of revenue in the 2024 financial report [1] - In the first quarter of 2025, the company achieved operating revenue of 215 million yuan and a net profit of 53.68 million yuan [1] Group 2 - On August 19, the company announced it received a medical device registration certificate from the Guangdong Provincial Drug Administration for its high-sensitivity cardiac troponin I assay kit, which uses electrochemical luminescence to detect myocardial injury markers [1] - The stock experienced a net outflow of 13.52 million yuan from main funds on the same day, with a cumulative net outflow of 23.95 million yuan over the past five days [1]

Core Viewpoint - Pumen Technology has received a medical device registration certificate for its high-sensitivity cardiac troponin I (hs-cTnISTAT) assay kit from the Guangdong Provincial Drug Administration [1] Company Summary - The product is classified as an in vitro diagnostic reagent and utilizes electrochemical luminescence technology [1]

Group 1 - Pumen Technology (SH 688389, closing price: 14.49 yuan) announced on August 19 that it has received a Medical Device Registration Certificate from the Guangdong Provincial Drug Administration for its product "High-Sensitivity Cardiac Troponin I Test Kit" [2] - For the year 2024, Pumen Technology's revenue composition is as follows: 98.56% from medical devices and 1.44% from other businesses [2]

证券代码：688389 证券简称：普门科技 公告编号：2025-062 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 一、医疗器械注册证的具体情况 | 产品名称 | | | | | 注册 | 注册证 | 注册证 | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 分类 | 编号 | 有效期至 | | | | 高 敏 心 肌 （hs-cTnI STAT）测定试 | 肌 | 钙 | 蛋 | 白 I | 类 II | 粤械注准 | 2030 | 年 | 用于体外定量测定人血清或血 浆中肌钙蛋白 （I cTnI）的含量。 | | | | | | | | 20252401126 | 月 日 8 | ...

格隆汇8月19日丨普门科技(688389.SH)公布，近期收到了1个广东省药品监督管理局颁发的《中华人民 共和国医疗器械注册证（体外诊断试剂）》，产品名称：高敏心肌肌钙蛋白I（hs-cTnISTAT）测定试剂 盒（电化学发光法）。心肌肌钙蛋白I（cTnI）是临床诊断中高度敏感的心肌损伤标志物。当心肌发生 损伤后，细胞中多种形式的心肌肌钙蛋白（包括I-C复合物、I-T-C三聚体以及游离肌钙蛋白I、游离肌钙 蛋白T）释放到血液中，导致外周血中cTnI浓度迅速上升。大量临床研究表明，在急性心肌梗死发病后 4-10小时，心肌肌钙蛋白会出现在血清中，其浓度在12-48小时达到峰值，并在随后4-10天内维持升高状 态。心肌肌钙蛋白水平的动态变化，是鉴别急性和慢性心肌损伤的关键，同时可以辅助诊断心肌梗死。 ...

Company Overview - Pumen Technology specializes in the research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The main products include medical products, home products, testing equipment, and testing reagents [2] Recent Achievements - In January 2024, Pumen Technology was awarded the "Smart Health and Elderly Care Application Pilot Demonstration - Demonstration Enterprise" by three ministries [2] - The project "Micro-tube Inner Surface Wear-resistant Superhydrophobic Coating and Its Application in Medical Devices" won the "2023 China Corrosion and Protection Society Science and Technology Award" first prize [2] - The subsidiary Guangdong Pumen Biomedical Technology Co., Ltd. was recognized as a "Specialized, Refined, Characteristic, and Innovative Small and Medium-sized Enterprise" by the Guangdong Provincial Department of Industry and Information Technology [2] - A collaborative project with Chongqing University on "Key Technology Development and Industrialization of Fully Automatic Specific Protein Analyzer" received the "2023 China Industry-University-Research Cooperation Innovation Achievement Award" second prize [2] Financial Performance - In Q1 2025, the company reported revenue of 215 million yuan, a year-on-year decrease of 29.69% [2] - Net profit for the same period was 53.68 million yuan, down 49.93% year-on-year [2] - The sales gross margin stood at 64.97% [2] Market Position - As of August 15, Pumen Technology's stock closed at 14.68 yuan, with a PE ratio of 21.55, marking a new low in 92 days [1] - The company's total market capitalization is 6.29 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 56.58 and a median of 39.97, Pumen Technology ranks 45th [1][3] Shareholder Information - As of March 31, 2025, Pumen Technology had 13,289 shareholders, an increase of 3,464 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

Group 1 - The core viewpoint of the news highlights the financial performance and market position of Pumen Technology, indicating a decline in revenue and profit for the first quarter of 2025, alongside a relatively low PE ratio compared to the industry average [1][2][3] Group 2 - Pumen Technology's main business includes research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The company achieved a revenue of 215 million yuan in Q1 2025, representing a year-on-year decrease of 29.69%, and a net profit of 53.68 million yuan, down 49.93% year-on-year, with a gross margin of 64.97% [2] - As of March 31, 2025, the number of shareholders increased to 13,289, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - Pumen Technology's current PE ratio is 20.98, while the industry average is 55.76, and the industry median is 39.14, placing the company at the 45th position in the industry ranking [1][3] - The company received several awards, including the "Smart Health Elderly Care Application Pilot Demonstration - Demonstration Enterprise" and the "2023 China Corrosion and Protection Society Science and Technology Award" [2]